Anoro Ellipta

  • Asthma/COPD

Anoro Ellipta Generic Name & Formulations

General Description

Umeclidinium 62.5mcg, vilanterol 25mcg; per ­inhalation; dry pwd for oral inhalation.

Pharmacological Class

Anticholinergic + long-acting beta-2 agonist (LABA).

How Supplied

Dry pwd inhaler—30 doses


Generic Availability


Anoro Ellipta Indications


Maintenance treatment of COPD.

Limitations of Use

Not indicated for relief of acute bronchospasm or for treatment of asthma.

Anoro Ellipta Dosage and Administration


1 inhalation once daily.


Not established.

Anoro Ellipta Contraindications


Severe allergy to milk proteins. Use of LABA without inhaled corticosteroid (ICS) in those with asthma.

Anoro Ellipta Boxed Warnings

Not Applicable

Anoro Ellipta Warnings/Precautions


LABA as monotherapy (without ICS) for asthma can increase risk of asthma-related events. Do not initiate in rapidly deteriorating or life-threatening COPD episodes. Prescribe a short-acting, inhaled β2-agonist for acute symptoms; monitor for increased need. Do not exceed recommended dose. Avoid use with other long-acting β2-agonists. Discontinue if paradoxical bronchospasm occurs; use alternative therapy. Cardiovascular disorders (esp. coronary insufficiency, arrhythmias, hypertension). Convulsive disorders. Thyrotoxicosis. Hyperresponsiveness to sympathomimetics. Diabetes. Ketoacidosis. Narrow-angle glaucoma. Urinary retention. Prostatic hyperplasia. Bladder-neck obstruction. Risk of hypokalemia or hyperglycemia. Labor & delivery. Pregnancy. Nursing mothers: not recommended.

Anoro Ellipta Pharmacokinetics

See Literature

Anoro Ellipta Interactions


Caution with concomitant strong CYP3A4 inhibitors (eg, ketoconazole, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole), MAOIs, tricyclic antidepressants, drugs known to prolong the QT interval or within 2 weeks of discontinuing such agents (increased cardiac effects), K+-depleting diuretics. Antagonized by β-blockers; if needed, consider cardioselective agents. Additive effects with concomitant other anticholinergic-containing drugs; avoid.

Anoro Ellipta Adverse Reactions

Adverse Reactions

Pharyngitis, sinusitis, lower respiratory tract infection, constipation, diarrhea, pain in extremity, muscle spasms, neck and chest pain; hypersensitivity reactions (discontinue if occurs).

Anoro Ellipta Clinical Trials

See Literature

Anoro Ellipta Note

Not Applicable

Anoro Ellipta Patient Counseling

See Literature